Clinical Trials – Traditional Model To view page on mobile device, activate QR Code above Recruiting Cancer Clinical Trials at Salinas Valley Health NRG-GI008 – Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)February 23, 2023 A012103 – Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabAugust 3, 2023 S2212 – Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III StudyFebruary 7, 2024 NRG-BR009 – Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)March 13, 2024 NRG-CC015: Harnessing E-Mindfulness Approaches for Living After Breast Cancer (HEAL-ABC)June 30, 2025 A012303 – ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabAugust 13, 2026 NRG-GY037: A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab Versus Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical CancerAugust 13, 2026
